Join us for the Policy Summit Sept. 25-26 at the Washington Marriott Georgetown in Washington, D.C.!
Read The Advocate Policy Summit
Read our correspondence with Congress, FDA, and other organizations, back to 2015.
Learn More
Learn about the Policy & Advocacy team's areas of focus, pipeline indications in the next five years, and more.
Through congressional advocacy, including one-on-one meetings with legislative staff, briefings, and letters, ASGCT advocates for federal funding for gene and cell therapy research.
ASGCT advocates for a predictable and efficient regulatory environment that supports safe and effective clinical translation of gene and cell therapies.
ASGCT has made it a priority to support dialogue and exchange of ideas as new gene and cell therapy technologies prompt new questions about their use.
ASGCT meets annually with FDA staff in the Office of Tissues and Advanced Therapies (OTAT) to share new developments, highlight ongoing challenges, and recommend solutions for the CGT field.
Since the surge in gene and cell therapy approvals and development, ASGCT has advocated for policies that support patient access to these products in a variety of ways.
To obtain access to, and maximal benefit from, potentially life-altering approved gene therapies, diagnosing patients as early as possible is critical. ASGCT advocates to federal policymakers to support access to genetic testing and screening.
ASGCT supports payment policies that facilitate patient access to approved gene and cell therapies, including full coverage of FDA-labeled indications, maximal reimbursement of providers, and the use of innovative payment mechanisms.
Sept. 25-26, 2025 | Washington, D.C.
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico